Curriculum Vitae

JOHN PETER BANTLE, M.D.

December 2022

Office Address: MMC 101
University of Minnesota
Minneapolis, MN 55455

Universities Attended:
1965 - 1968 University of Minnesota, Minneapolis, Minnesota
1968 - 1972 University of Minnesota Medical School, Minneapolis, Minnesota

Degrees:
1970 Bachelor of Science
1972 Doctor of Medicine

Professional Training:

Internship
Rotating Internship with medicine emphasis
Cleveland Metropolitan General Hospital
Cleveland, Ohio
July 1972 - June 1973

Residency

Internal Medicine
Mayo Clinic
Rochester, Minnesota
July 1973 - September 1975

Internal Medicine (Registrar)
Dunedin Public Hospital
Dunedin, New Zealand
November 1975 - February 1976

Fellowship
Endocrinology and Metabolism
University of Minnesota
Minneapolis, Minnesota
July 1976 - June 1978

State License: Minnesota (No. 21141)

Board Certification:
1975 American Board of Internal Medicine (certification number 50035)
1979 Endocrinology and Metabolism (certification number 50035)

Professional Experience:

Instructor, Department of Medicine
University of Minnesota Medical School
July 1978 - June 1979

Assistant Professor, Department of Medicine
University of Minnesota Medical School
July 1979 - June 1987

Associate Professor, Department of Medicine
University of Minnesota Medical School
July 1987 - June 1996

Professor, Department of Medicine
University of Minnesota Medical School
July 1996 - December 2016

Professor Emeritus
University of Minnesota Medical School
January 2017 - present

Associate Director, General Clinical Research Center
University of Minnesota Medical School
July 1983 - November 2009

Medical Staff Clinical Service Chief for Internal Medicine
Fairview-University Medical Center
January 2001 - May 2007

Interim Director, Division of Endocrinology and Diabetes
Department of Medicine
University of Minnesota Medical School
October 2008 - April 2010

Director, Division of Endocrinology and Diabetes
Department of Medicine
University of Minnesota Medical School
May 2010 – March 2015

Leader, Clinical Research Implementation Services (CRIS)
Clinical and Translational Science Institute (CTSI)
University of Minnesota
August 2011 - 2013

Membership in Organizations:

American Diabetes Association
The Endocrine Society

Honors and Awards:

Alpha Omega Alpha, University of Minnesota Medical School, 1972

Nominated for Minnesota Medical Foundation Distinguished Clinical Teacher Award in 1992 and 1993

Recipient of Department of Medicine 2002 Clinical Excellence Award

Recipient of Department of Medicine 2004 Clinical Excellence Award

Recipient of Department of Medicine 2011 Clinical Excellence Award

Named in the Minneapolis/St. Paul Magazine surveys of Twin Cities doctors and nurses as a leading doctor in his specialty; i.e., one they would pick for their own care, in 1992, 1994, 1996, 1999, 2000, 2001, 2002, 2004, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016 and 2017.

Selected by peers to be included in Best Doctors in America 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016 and 2017.

Service at the National Level

Member of the American Diabetes Association Committee which developed 1994 diabetes nutrition recommendations

Member of the American Diabetes Association Committee which developed the 1998 standards of care for people with diabetes

Co-Chair of the American Diabetes Association Committee which developed 2002 diabetes nutrition recommendations

Co-Chair of the American Diabetes Association Committee which developed 2006 diabetes nutrition recommendations

Service to the University

Elected member University of Minnesota Physicians Board of Directors (2006 - 2009)

Elected member University of Minnesota Senate (1999 - 2002, 2007 - 2010)

Service to the Department of Medicine

Medical Staff Clinical Service Chief (2001 - 2007)

Elected member Department of Medicine Board of Governors (two terms, 1999 - 2005)

Member Promotion and Tenure Committee (1997 - 2003)

Medical Director, Diabetes Education and Self-Management Program (1995 - 2000)

Selected Regional, National and International Lectures and Symposia:

Postprandial Responses to Meals Containing Sugars and Starches. NIH Seminar of Nutrition Coordinating Committee, Bethesda, MD, September 8, 1983.

Metabolic Effects of Dietary Fructose. American Medical Association Resource Conference on Fructose, Chicago, IL, October 1-2, 1984.

Effects of Dietary Sucrose and Fructose. NIH Diabetes Update, Bethesda, MD, March 30, 1985.

The Glycemic Effects of Dietary Carbohydrates. NIH Consensus Development Conference on Diet and Exercise in NIDDM, Bethesda, MD, December 8-10, 1986.

Dietary Fructose and Sucrose in People with Diabetes. UCSF and Northern California American Diabetes Association Affiliate Symposium on Sweeteners in Diabetes, San Francisco, CA, March 20, 1987.

Dietary Carbohydrates and their Effect on Plasma Glucose. American Diabetes Association Symposium on Nutrition and Metabolism, San Francisco, CA, October 6-8, 1988.

Current Controversy: Carbohydrate and Fat. American Diabetes Association Council on Nutritional Sciences and Metabolism, Las Vegas, NV, June 12, 1993.

Diabetes Control and Complications Update. American Dietetic Association National Meeting, Anaheim, CA, October 28, 1993.

Nutritional Issues in the Management of NIDDM. American Diabetes Association Annual Advanced Postgraduate Course, Boston, MA, January 28-30, 1994.

Controversies in the Nutritional Management of Diabetes. University of Iowa, Iowa City, IA, April 27, 1995.

Current Trends in Obesity Management for Diabetes. American Diabetes Association Utah Affiliate, Salt Lake City, UT, May 12, 1997.

Health Implications of Obesity: A Focus on Diabetes. American Diabetes Association Annual Meeting, Boston, MA, June 21, 1997.

Current Nutrition Recommendations of the American Diabetes Association. American College of Nutrition Annual Meeting, New York, NY, September 27, 1997.

Obesity and Type 2 Diabetes. Video Conference sponsored by the University of Minnesota and the American Diabetes Association, New York, NY, February 25, 1998.

Intensive Treatment of Type 1 Diabetes Mellitus. St. Louis University, St. Louis, MO, October 5, 2001.

Evidence Based Nutrition Recommendations for Diabetes: 2001. American Dietetic Association National Meeting, St. Louis, MO, October 21, 2001.

Glycemic Index: Scientific Merit and Clinical Utility. American Diabetes Association Annual Meeting, San Francisco, CA, June 15, 2002.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0003

MPI EXHIBIT 1004 PAGE 3

A Combination of Food Based Strategies and Pharmacotherapy for Weight Reduction in Type 2 Diabetes. European Congress on Obesity, Helsinki, Finland, May 30, 2003.

Prevention and Treatment of Diabetes Mellitus. St. Louis University, St. Louis, MO, November 7,2003.

Weight Loss as Primary Therapy for Type 2 Diabetes Mellitus. National (Mexican) Congress on Diabetes, Acapulco, Mexico, March 10, 2005.

Is Fructose the Optimal Low Glycemic Index Sweetener? Nestle Symposium on Nutritional Management of Diabetes Mellitus and Dysmetabolic Syndrome, Hangzhou, China, October 30 – November 2, 2005 (meeting Co-Chairman).

Do Fructose and Sugar Alcohols make a Difference in Diabetes and Weight Control? American Diabetes Association Annual Advanced Postgraduate Course, San Francisco, CA, February 11, 2006.

Nutrition Guidelines for Diabetes – A Focus on Carbohydrates. Satellite Symposium, International Diabetes Federation World Congress, Cape Town, South Africa, December 6, 2006.

Keynote: Management of Type 2 Diabetes. University of Nebraska conference Management of Diabetes and Complications, Omaha, NE, March 30, 2007.

Factors to Consider when Conducting Research on Fructose and Metabolic Syndrome and Diabetes. ILSI North America and United States Department of Agriculture Symposium on The State of the Science on Dietary Sweeteners Containing Fructose, Beltsville, MD, March 19-19, 2008.

Non-Pharmacologic Therapy of Type 2 Diabetes. Meet-the-Professor Session. Endocrine Society Annual Meeting, San Francisco, CA, June 16, 2008.

The Diabetes Epidemic. CME Institute, Maui, HI, March 1, 2010.

Bariatric Surgery and Type 2 Diabetes: For Whom, How and At What Point in the Natural History? American Diabetes Association 58th Annual Advanced Postgraduate Course, New York, NY, February 27, 2011.

Clinical Research Strategies for Fructose Metabolism, NIH, Bethesda, MD, November 13-14, 2012 (Session I Chair).

Metabolic Surgery: Advantages and Disadvantages. American Diabetes Association 60th Annual Advanced Postgraduate Course, New York, NY, February 24, 2013.

Bariatric Surgery as Treatment for Type 2 Diabetes Mellitus: An Endocrinologist's Perspective. Fifth Asian Diabetes Surgery Summit, Taipei, Taiwan, October 25, 2014.

Post-Bariatric Surgery Hypoglycemia. Meet-the-Professor Session. Endocrine Society Annual Meeting, Boston, MA, April 2, 2016.

Post-Bariatric Surgery Hyperinsulinemic Hypoglycemia. University of Indiana, Indianapolis, IN, February 8, 2017.

Medical Approach to Obesity Management. Seventh Emirates Diabetes and Endocrine Congress. Dubai, United Arab Emirates, February 17, 2017.

Areas of Research Interest:

1. Intensive treatment of diabetes mellitus
2. Dietary treatment of diabetes mellitus
3. Metabolic effects of dietary carbohydrates
4. Treatment of obesity

Chronology of Grants and Research Support as Principal Investigator or Co-Principal Investigator:

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0004

MPI EXHIBIT 1004 PAGE 4

Archer, Daniels, Midland Foundation (1981-1983) $12,000
"Plasma Glucose Response to Various Forms of Dietary Carbohydrate"

Sandoz, Inc. (1983-1984) $7,000
"Potassium Clearance in Renal Transplant Recipients Receiving Cyclosporine"

American Diabetes Association, Inc. (1983-1985) $49,568
"Comparison of Fructose, Sucrose and Starch in the Diabetic Diet"

The Estee Corporation (1983-1985) $14,000
"Comparison of Fructose, Sucrose and Starch in the Diabetic Diet"

Sandoz, Inc. (1984-1986) $17,920
"Effects of Cyclosporine on the Renin-Angiotensin-Aldosterone System"

American Diabetes Association, Minnesota Affiliate (1985-1986) $5,000
"Comparison of the Diabetic Exchange Lists and the Glycemic Index of Foods"

Public Health Service, NIH NIDDK (1985-1996) $2,732,116
"Diabetes Control and Complications Trial (DCCT)"

Sandoz, Inc. (1987-1988) $15,000
"Trial of Alpha Adrenergic Blockade to Prevent Cyclosporine Nephrotoxicity"

The International Fructose Association (1987-1991) $100,000
"Metabolic Effects of Chronic Dietary Fructose and Sucrose Consumption"

Eli Lilly and Company (1989) $4,700
"Effects of Rotating Insulin Injection Sites in Type I Diabetic Subjects"

Roerig Division, Pfizer Incorporated (1990-1992) $100,385
"Effects of Two Different Dietary Regimens on Glucose and Lipid Metabolism in Glipizide Treated Patients with NIDDM"

Integ, Inc. (1996-1997) $35,933
"The Use of Dermal Interstitial Fluid for Glucose Monitoring"

American Diabetes Association (1997-1998) $72,406
"Pharmacologic Induction of Weight Loss to Treat Type 2 Diabetes Mellitus"

Smith Kline Beecham Pharmaceuticals (1998) $10,000
"Plasma Serotonin in Fenfluramine and Phentermine Treated Patients"

Medtronic, Inc. (1999-2000) $29,834
"ECG Analysis for Blood Glucose Monitoring"

Abbott Laboratories and Slim Fast Foods Company (2000-2003) $333,297
"Combination Weight Loss Therapy for Type 2 Diabetes Mellitus"

Public Health Service, NIH NHLBI (2001-2010) $1,115,950
"Bypass Angioplasty Revascularization 2 Diabetes (BARI 2D)"

Public Health Service, NIH NIDDK (2002-2022) $1,393,783 for most recent 5 years
"Action for Health in Diabetes Extension Study (Look AHEAD)"

Role: Co-Principal Investigator,

Current Grant Support:

Public Health Service, NIH NIDDK (7/1/2017-6/30/2022) $157,894 for current year
"Epidemiology of Diabetes Intervention and Complications (EDIC)"
Role: Principal Investigator, 6% effort

Publications in Peer Reviewed Journals

1. Bantle JP, Dillmann WH, Oppenheimer JH, Bingham C, Runger GC. Common clinical indices of thyroid hormone action: relationships to serum free T_3 concentration and estimated nuclear occupancy. *J Clin Endocrinol Metab* 1980;50:286-293.
2. Bantle JP, Oppenheimer JH, Schwartz HL, Hunninghake DB, Probstfield JL, Hanson RF. TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. *Metabolism* 1981;30:63-66.
3. Schuster LD, Bantle JP, Oppenheimer JH, Seljeskog EL. Acromegaly: reassessment of the long-term therapeutic effectiveness of transphenoidal pituitary surgery. *Ann Intern Med*. 1981;95:172-174.
4. Bantle JP, Seelig S, Mariash CN, Ulstrom RA, Oppenheimer JH. Resistance to thyroid hormones: a disorder frequently confused with Graves' disease. *Arch Intern Med* 1982; 142:1867-1871. Summarized in *1984 Year Book of Medicine.*
5. Mitchell JE, Bantle JP. Metabolic and endocrine investigations in women of normal weight with the bulimia syndrome. *Biol Psychiatry* 1983;18:355-365.
6. Bantle JP, Beyer S, Oppenheimer JH. Recurrent episodes of spontaneously resolving hyperthyroidism due to thyroiditis. *Minn Med* 1983;66:295-297.
7. Bantle JP, Laine DC, Castle GW, Thomas JW, Hoogwerf BJ, Goetz FC. Postprandial glucose and insulin responses to meals containing sugars or starches in normal and diabetic subjects. *N Engl J Med* 1983;309:7-12. Summarized in *1984 Year Book of Medicine.*
8. Hoogwerf BJ, Barbosa JJ, Bantle JP, Laine DC, Goetz FC. Urinary C-peptide as a measure of beta cell function following a mixed meal in healthy subjects: comparison of four hour urine C-peptide with serum insulin and plasma C-peptide. *Diabetes Care* 1983; 6:488-492.
9. Bantle JP, Laine DC, Hoogwerf BJ, Goetz FC. The potential usefulness of postprandial urine C-peptide measurement in classifying diabetic patients. *Diabetes Care* 1984;7:202-203 (letter).
10. Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID, Hunninghake DB. Treatment of type III hyperlipoproteinemia with four different treatment regimens. *Atherosclerosis* 1984;51: 251-259.
11. Mascioli SR, Bantle JP, Freier EF, Hoogwerf BJ. Artifactual elevation of serum creatinine due to fasting. *Arch Intern Med* 1984;144:1575-1576. Summarized in *1985 Year Book of Medicine.*
12. Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH. Comparison of the effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in the treatment of hypercholesterolemia. *Am J Med* 1984;77:475-481.
13. Bantle JP, Nath KA, Sutherland DER, Najarian JS, Ferris TF. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium clearance in renal transplant recipients. *Arch Intern Med* 1985;145:505-508. Summarized in *1986 Year Book of Medicine.*
14. Beyer HS, Bantle JP, Mariash CN, Steffes MW, Seljeskog EL, Oppenheimer JH. Use of the dexamethasone-adrenocorticotropin test to assess the requirement for continued glucocorticoid replacement therapy after pituitary surgery. *J Clin Endocrinol Metab* 1985;60:1012-1018.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0006

MPI EXHIBIT 1004 PAGE 6

15. Bantle JP, Lee CKK, Levitt SH. Thyroxine administration during radiation therapy to the neck does not prevent subsequent thyroid dysfunction. *Int J Radiat Oncol Biol Phys*. 1985;11:1999-2002.
16. Hoogwerf BJ, Bantle JP, Gaenslen HE, Greenberg BZ, Senske BJ, Francis R, Goetz FC. Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects. *Metabolism* 1986;35:122-125.
17. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. *Diabetes* 1986;35:530-545.
18. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in type I and type II diabetic subjects. *JAMA* 1986;256:3241-3246.
19. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): results of the feasibility study (phase II). *Diabetes Care* 1987;10:1-19.
20. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism: Role of T3 in pituitary feedback in man. *N Engl J Med* 1987;316:764-770.
21. Laine DC, Thomas JW, Levitt MD, Bantle JP. Comparison of the predictive capabilities of the diabetic Exchange Lists and the Glycemic Index of Foods. *Diabetes Care* 1987; 10:387-394.
22. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. *Am J Med* 1987;83:59-64.
23. Bantle JP, Laine DC. Day-to-day variation in glycemic control in type I and type II diabetes mellitus. *Diabetes Res* 1988;8:147-149.
24. Bantle JP, Paller MS, Boudreau RJ, Olivari MT, Ferris TF. Long-term effects of cyclosporine on renal function in organ transplant recipients. *J Lab Clin Med* 1990;115:233-240.
25. Bantle JP, Weber MS, Rao SMS, Chattopadhyay MK, Robertson RP. Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. *JAMA* 1990;263:1802-1806. Summarized in *1991 Year Book of Medicine.*
26. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Update. *Diabetes Care* 1990;13:427-433.
27. Swanson JE, Laine DC, Thomas W, Bantle JP. Metabolic effects of dietary fructose in healthy subjects. *Am J Clin Nutr* 1992;55:851-856.
28. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary fructose in diabetic subjects. *Diabetes Care* 1992;15:1468-1476.
29. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-986. Summarized in *1994 Year Book of Medicine.*
30. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary sucrose in type II diabetic subjects. *Diabetes Care* 1993;16:1301-1305.
31. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetic subjects. *Diabetes Care* 1993;16:1592-1597.
32. Garg A, Bantle JP, Henry RR, Coulston AM, Griver K, Raatz SK, Brinkley L, Chen YD, Grundy SM, Huet BA, Reaven GM. Long-term effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. *JAMA* 1994;271:1421-1428.
33. Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. *Ann Intern Med* 1994;121:152 (letter).
34. The DCCT Research Group. Implementation of conventional and intensive treatment in the Diabetes Control and Complications Trial. *Diabetes Care* 1995;18:361-375.
35. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. *Arch Ophthalmol* 1995;113:36-51.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0007

MPI EXHIBIT 1004 PAGE 7

36. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy in the Diabetes Control and Complications Trial. *Ann Intern Med* 1995;122:561-568.
37. The DCCT Research Group. The effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. *Kidney Int* 1995;47:1703-1720.
38. Bhatia S, Ramsay NKC, Bantle JP, Martens A, Robison LL. Thyroid abnormalities after therapy for Hodkins Disease in childhood. *The Oncologist* 1996;1:62-67.
39. Bantle JP, Thomas W. Glucose monitoring using dermal interstitial fluid. *J Lab Clin Med* 1997;130:436-441.
40. Redmon B, Raatz SR, Bantle JP. Valvular heart disease associated with fenfluramine-phentermine. *N Engl J Med* 1997; 337:1773-1774 (letter).
41. Georgopoulos A, Bantle JP, Swaim WR, Parker SJ. Differences in the metabolism of postprandial lipoproteins during a high monounsaturated fat versus a high carbohydrate diet in patients with IDDM. *Arterioscler Thromb Vasc Biol* 1998;18:773-782.
42. The EDIC Research Group. Epidemiology of Diabetes Intervention and complications (EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort. *Diabetes Care* 1999;22:99-111.
43. Redmon JB, Raatz SK, Kwong C, Swanson J, Thomas JW, Bantle JP. Pharmacologic induction of weight loss to treat type 2 diabetes mellitus. *Diabetes Care* 1999;22:896-903.
44. The EDIC Research Group. The effect of intensive diabetes treatment on carotid artery wall thickness in the Epidemiology of Diabetes Interventions and Complications (EDIC). *Diabetes* 1999;48:383-390.
45. The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. *N Engl J Med* 2000;342:381-389.
46. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. *Am J Cardiol* 2000;85:913-915.
47. The DCCT Research Group. Effects of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. *Diabetes Care* 2000;23:1084-1091.
48. Bantle JP, Raatz SK, Georgopoulos A, Thomas W. Effects of dietary fructose on plasma lipids in healthy subjects. *Am J Clin Nutr* 2000;72:1128-1134.
49. Georgopoulos A, Bantle JP, Noutsou M, Hoover HA. A high carbohydrate versus a high monounsaturated fatty acid diet lowers the atherogenic potential of big VLDL particles in patients with type 1 diabetes. *J Nutr* 2000;130:2503-2507.
50. The DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med* 2003;348:2294-2303.
51. The DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA* 2003; 290:2159-2167.
52. Redmon JB, Raatz SA, Reck KP, Swanson JE, Kwong CA, Fan Q, Thomas W, Bantle JP. A combination of weight loss therapies for subjects with type 2 diabetes mellitus. *Diabetes Care* 2003;26:2505-2511.
53. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. *Control Clin Trials* 2003;24;610-628.
54. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in persons with type 1 diabetes mellitus. *Diabetes Care* 2004;27:1209-1210.
55. Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Hong J, Thomas W, Bantle JP. Two year outcome of a combination of weight loss therapies for type 2 diabetes. *Diabetes Care* 2005;28:1311-1315.
56. Raatz, SK, Torkelson CJ, Redmon JB, Reck KP, Kwong CA, Swanson JE, Chengcheng L, Thomas W, Bantle JP. Reduced glycemic index and glycemic load diets do not

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0008

MPI EXHIBIT 1004 PAGE 8

increase the effects of energy restriction on weight loss and insulin sensitivity in obese men and women. *J Nutr* 2005;135:2387-2391.
57. Shah M, Adams-Huet B, Bantle JP, Henry RR, Griver KA, Raatz SK, Brinkley LJ, Reaven GM, Garg A. Effect of a high-carbohydrate versus a high-cis-monounsaturated fat diet on blood pressure in patients with type 2 diabetes. *Diabetes Care* 2005;28:2607-2612.
58. The DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:2643-2653.
59. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ for the BARI 2D Trial Investigators. Hypotheses, design and methods for the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Am J Cardiol* 2006;97[suppl]:9G-19G.
60. Look AHEAD Research Group. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. *Obesity* 2006;14:737-752.
61. Bantle JP, Ikramuddin S, Kellogg TA, Buchwald H. Hyperinsulinemic hypoglycemia developing late after gastric bypass. *Obesity Surgery* 2007;17:592-594.
62. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes. *Diabetes Care* 2007;30:1374-1383.
63. Bantle AE, Thomas W, Bantle JP. Metabolic effects of alcohol in the form of wine in persons with type 2 diabetes mellitus. *Metabolism* 2008;57:241-245.
64. Bertoni AG, Clark JM, Feeney P, Yanovski SZ, Bantle J, Montgomery B, Safford MM, Herman WH, Haffner S and the Look AHEAD Research Group. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. *J Diabetes Complications* 2008;22:1-9.
65. BARI 2D Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Am Heart J* 2008;156:528-536.
66. Kellogg TA, Bantle JP, Leslie DB, Redmon JB, Slusarek B, Swan T, Buchwald H, Ikramuddin S. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. *Surg Obes Relat Dis* 2008;4:492-499.
67. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360:2503-2515.
68. The DCCT/EDIC Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration. *Arch Intern Med* 2009;169:1307-1316.
69. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes. *Arch Intern Med* 2010;170:1566-1575.
70. The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011;365:2366-2376.
71. Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, Bantle JP, Johnson RJ, Diehl AM, Clark JM and the Fatty Liver Subgroup of the Look AHEAD Research Group. Higher dietary fructose is associated with impaired hepatic ATP homeostasis in obese individuals with type 2 diabetes. *Hepatology* 2012;56:952-960.
72. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford M, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG and the Look AHEAD Research Group**.** Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA* 2012;308:2489-2496.
73. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for control of type 2 diabetes, hypertension and hyperlipidemia: The diabetes surgery study randomized clinical trial. *JAMA* 2013;309:2240-2249.
74. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013;369:145-154.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0009
MPI EXHIBIT 1004 PAGE 9

75. Khowaja A, Johnson-Rabbett B, Bantle J, Moheet A. Hypoglycemia mediated by paraneoplastic production of insulin like growth factor-2 from a malignant renal solitary fibrous tumor. *BMC Endocrine Disorders* 2014;14:49.
76. The Look AHEAD Research Group. Effect of long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol* 2014;2:801-809.
77. DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. *JAMA* 2015;313:45-53.
78. Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet WB, Jeffery RW, Keong C, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Reynolds AE, Bainbridge HA, Wang Q, Korner J. Benefits and risks of roux-en-Y gastric bypass for diabetes: two year outcomes of the diabetes surgery study. *Lancet Diabetes Endocrinol* 2015; 3:413-422.
79. Bantle AE, Wang Q, Bantle JP. Post-gastric bypass hyperinsulinemic hypoglycemia: fructose is a carbohydrate which can be safely consumed. *J Clin Endocrinol Metab* 2015;100:3097-3102.
80. Nguyen KT, Billington CJ, Vella A, Wang Qi, Ahmed L, Bantle JP, Bessler M, Connett, JE, Inabnet WB, Thomas A, Ikramuddin S, Korner J. Preserved insulin secretory capacity and weight loss are the predominant predictors of glycemic control in patients with type 2 diabetes randomized to roux-en-Y gastric bypass. *Diabetes* 2015;64:3104-3110.
81. Ikramuddin S, Korner J, Lee W-J, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet WB, Wang Q, Jeffery RW, Chong K, Chuang L-M, Jensen MD, Vella A, Ahmed L, Belani K, Olofson AE, Bainbridge HA, Billington CJ. Durability of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled diabetes in mild to moderate obesity: a randomized clinical trial. *Diabetes Care* 2016;39:1510-1518.
82. DCCT/EDIC Research Group. Risk factors for cardiovascular disease in type 1 diabetes. *Diabetes* 2016;65:1370-1379.
83. Buchwald H, Oien DM, Schieber DJ, Bantle JP, Connett JE. Partial ileal bypass affords protection from onset of type 2 diabetes. *Surg Obes Relat Dis* 2017;13:45-52.
84. Chong K, Ikramuddin S, Lee W, Billington CJ, Bantle JP, Wang Q, Thomas AJ, Connett JE, Leslie DB, Inabnet WB, Jeffery RW, Sarr MG, Jensen MD, Vella A, Ahmed L, Belani K, Schone JL, Olofson AE, Bainbridge HA, Laqua PS, Korner J, Chuang L. National differences in remission of type 2 diabetes mellitus after roux-en-Y gastric bypass surgery - subgroup analysis of 2-year results of the diabetes surgery study comparing Taiwanese with Americans with mild obesity (BMI 30-35 kg/m^2). *Obes Surg* 2017;27:1189-1195.
85. Purnell JQ, Braffett BH, Zinman B, Hokanson JE, Gubitoski-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD and the DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complication Study (DCCT/EDIC*). Diabetes Care* 2017;40:1756-1762.
86. Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, Leslie DB, Wang Q, Inabnet WB, Jeffery RW, Chong K, Chuang LM, Jensen MD, Vella A, Ahmed L, Belani K, Billington CW. Lifestyle intervention and medical management with vs without roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the diabetes surgery study. *JAMA* 2018;319:266-278.
87. Genuth SM, Vlachos H, Brooks MM, Bantle JP, Chaitman BR, Green J, Kelsey SF, King SB, McBane R, Sako EY, Schneider DJ, Steffes M, Frye RL and the BARI 2D Study Group. Bypass Angioplasty Revascularization Investigation 2 Diabetes: A reanalysis focusing on cardiovascular events. *Mayo Clin Proc* 2019;94:2249-2262.
88. Wadden TA, Chao AM, Bahnson JL, Bantle JP, Blackburn GL, Clark JM, Gaussoin S, Jakicic JM, Johnson KC, Miller GD, Uniick JL, Yanovski SL. End-of-trial health

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0010

MPI EXHIBIT 1004 PAGE 10

outcomes in Look AHEAD participants who elected to have bariatric surgery. *Obesity* 2019;27:581-590.

89. Yeh H-C, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM, Coday M, Egan C, Espeland MA, Foreyt JP, Garcia K, Goldman V, Gregg EW, Hazuda HP, Hesson L, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Knowler WC, Korytkowski M, Kure A, Lewis CE, Mantzoros C, Meacham M, Montez MG, Nathan DM, Pajewski N, Patricio J, Peters A, Pi-Sunyer FX, Pownall H, Ryan DH, Safford M, Sedjo RL, Steinburg H, Vitolins M, Wadden TA, Wagenknecht LE, Wing RR, Wolff AC, Wyatt H, Yanovski SZ. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial. *Obesity* 2020;28:1678-1686.
90. Perkins BA, Bebu I, de Boer IH, Molitch M, Zinman B, Bantle JP, Lorenzi GM, Nathan DM, Lachin JM and the DCCT/EDIC Research Group . Optimal frequency of urinary albumin screening in type 1 diabetes. *Diabetes Care* 2022;45:2943-2949.
91. Bebu I, Braffett BH, De Boer IH, Aiello LP, Bantle JP, Lorenzi GM, Herman WH, Gubitoski-Klug RA, Perkins BA, Lachin JM, Molitch ME and the DCCT/EDIC Research Group. Relationships between the cumulative incidences of long-term complications in type 1 diabetes mellitus: the DCCT/EDIC Study. *Diabetes Care.* In press.

Book Chapters, Reviews, and Other Publications

1. Bantle JP, Oppenheimer JH. Laboratory assessment of thyroid function. In: Najarian JS, Delaney JP, eds., Endocrine Surgery. New York: Prentice Hall, 1981; pp. 295-307.
2. Bantle JP. Recent advances in the evaluation and treatment of diabetes mellitus. In: Bernstein E, ed., Encyclopaedia Britannica 1985 Medical and Health Annual. Chicago: Encyclopaedia Brittanica, Inc., 1984; pp. 235-240.
3. Bantle JP, Oppenheimer JH. Differentiated thyroid carcinoma. In: Hollander VP, ed., Hormonally Responsive Tumors. Orlando, Florida: Academic Press, 1985; pp. 529-540.
4. Bantle JP. Replacement therapy with levothyroxine: Evolving concepts. *Thyroid Today* 1987; 10:1-7.
5. Bantle JP. The dietary treatment of diabetes mellitus. *Med Clin North Am* 1988; 72:1285-1299.
6. Bantle JP. Clinical aspects of sucrose and fructose metabolism. *Diabetes Care* 1989; 12:56-61.
7. Bantle JP. Injection site rotation: the downside. *Practical Diabetology* 1990; 9:1-4.
8. Zeher C, Hansen R, Bantle JP. Reducing blood glucose variability by use of abdominal insulin injection sites. *Diabetes Educ* 1990; 16:474-477.
9. Bantle JP. Thoughts on the dietary treatment of diabetes mellitus. *Diabetes Care* 1992; 15:1821-1823.
10. Wheeler ML, Franz M, Heins J, Schafer R, Holler H, Bohannon B, Bantle JP, Barrier P. Food labeling. *Diabetes Care* 1994; 17:480-487.
11. Franz MJ, Horton ES, Bantle JP, Beebe CA, Brunzell JD, Coulston AM, Henry RR, Hoogwerf BJ, Stacpoole PW. Nutrition principles for the management of diabetes and related complications. *Diabetes Care* 1994;17:490-518.
12. Bantle JP. Current recommendations regarding the dietary treatment of diabetes mellitus. *The Endocrinologist* 1994;4:189-195.
13. Bantle JP. Sugar substitutes, blood glucose levels, and the diabetic diet. *Consultant* 1995;35:1599-1600.
14. Bantle JP. Diabetes mellitus: guide to implementing intensive therapy. *Consultant* 1996; 36:2353-2362.
15. Bantle JP. How to recognize and manage hypoglycemia in diabetes. *Consultant* 1996; 36:2363-2364.
16. Bantle JP. New approaches for the treatment of obesity. *The Bulletin* 1996;40:81-85.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0011
MPI EXHIBIT 1004 PAGE 11

17. Bantle JP, Robertson RP. New approaches to the treatment of type II diabetes mellitus. *Hospital Medicine* 1997;33:19-34.
18. Bantle JP. The adrenal cortex. In: Niewoehner CB, ed., Endocrine Pathophysiology. Madison, Connecticut: Fence Creek, 1998; pp. 61-76.
19. Bantle JP. A physician's perspective on medical nutrition therapy for diabetes. In: Franz MJ, Bantle JP, eds. American Diabetes Association Guide to Medical Nutrition Therapy for Diabetes. Alexandria, VA: American Diabetes Association, 1999; pp. 18-25.
20. Bantle JP. Weight-loss treatments for overweight individuals with diabetes. In: Franz MJ, Bantle JP, eds. American Diabetes Association Guide to Medical Nutrition Therapy for Diabetes. Alexandria, VA: American Diabetes Association, 1999; pp. 69-82.
21. Bantle JP. Diabetes Mellitus. Best Doctors: Information when it matters most; 2000: www.bestdoctors.com.
22. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M. Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 2002;25:148-198.
23. Bantle JP. Impaired fasting glucose: when and how to intervene. *Consultant* 2002; 42:672.
24. Franz MJ, Warshaw H, Daly AE, Green-Pastors J, Arnold MS, Bantle J. Evolution of diabetes medical nutrition therapy. *Postrgrad Med* 2003;79:30-35.
25. Bantle JP. Diabetes update 2003. *Audio-Digest Family Practice* 2003;51, issue 36.
26. Bantle JP. Weight management and type 2 diabetes. Medscape Diabetes and Endocrinology 2004;6:www.medscape.com.
27. Bantle JP. Advances in the care of diabetic patients. *Audio-Digest Family Practice* 2004; 52, issue 32.
28. Bantle JP. Diabetes update. *Audio-Digest Family Practice* 2005; 53, issue 44.
29. Bantle JP. Is fructose the optimal low glycemic index sweetener? In: Bantle JP, Slama G, eds., Nutritional Management of Diabetes and Dysmetabolic Syndrome. Basel, Switzerland: Karger, 2006; pp. 83-95.
30. American Diabetes Association (Bantle JP and Wylie-Rosett J, Co-Chairs of writing panel). Nutrition recommendations and interventions for diabetes-2006. *Diabetes Care* 2006;29:2140-2157.
31. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care* 2008;31:S61-S78.
32. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Poires WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med* 2009;122:248-256.
33. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. *J Nutr* 2009;139: 1263S-1268S.
34. Laughlin MR, Bantle JP, Havel PJ, Parks E, Klurfeld DM, Teff K, Maruvada P. Clinical research strategies for fructose metabolism. *Adv Nutr* 2014;5:248-259.

Apotex v. Novo - IPR2024-00631
Petitioner Apotex Exhibit 1004-0012

MPI EXHIBIT 1004 PAGE 12